Monogenic Kidney Diseases in Kidney Transplantation

Valentine Gillion; Arnaud Devresse; Eric Olinger; Géraldine Dahlqvist; Nathalie Demoulin; Nathalie Godefroid; Kathleen Claes; Olivier Devuyst; Nada Kanaan

doi:10.1016/j.ekir.2023.12.003

Monogenic Kidney Diseases in Kidney Transplantation

Kidney Int Rep. 2023 Dec 13;9(3):549-568. doi: 10.1016/j.ekir.2023.12.003. eCollection 2024 Mar.

Authors

Valentine Gillion^{1

2}, Arnaud Devresse^{1

2

3}, Eric Olinger⁴, Géraldine Dahlqvist^{2

5}, Nathalie Demoulin^{1

2}, Nathalie Godefroid^{2

6}, Kathleen Claes⁷, Olivier Devuyst^{1

2

8}, Nada Kanaan^{1

2}

Affiliations

¹ Department of Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
² Institut de Recherche Experimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
³ Surgery and Abdominal Transplant Unit, University Clinics Saint Luc, Université Catholique de Louvain, Brussels, Belgium.
⁴ Center for Human Genetics, Cliniques universitaires Saint-Luc, Brussels, Belgium.
⁵ Liver Transplant Unit, Cliniques universitaires Saint-Luc, Brussels, Belgium.
⁶ Department of Pediatric Nephrology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
⁷ Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
⁸ Institute of Physiology, University of Zurich, Zurich, Switzerland.

Abstract

Monogenic kidney diseases are involved in up to 15% of end-stage kidney diseases (ESKDs) in adults, and in 70 % of pediatric patients. When these disorders lead to kidney failure (KF), kidney transplantation (KT) is the preferred mode of replacement therapy. KT requires specific considerations depending on the nature of the genetic disorder, the potential oncological risk, the risk of recurrence in the graft, the possibility of specific complications of immunosuppression, and the issue of living donation. The availability of genetic testing should play an increasing role in the evaluation of patients or related living donor candidates before transplantation, relevant for the pretransplantation and posttransplantation management.

Keywords: Mendelian diseases; genetic testing; immunosuppression; living donation; oncological transformation; recurrence risk.

Publication types

Review